Secukinumab-Induced Lymphocytic Colitis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096221110399
Abstract: Secukinumab an interleukin-17 (IL-17) monoclonal antibody inhibitor is currently approved for the treatment of rheumatological conditions, such as psoriasis and ankylosing spondylitis. Lymphocytic colitis, a phenotype of microscopic colitis, is a long-term inflammatory condition, is… read more here.
Keywords: secukinumab induced; lymphocytic colitis; colitis; induced lymphocytic ... See more keywords